Greer, TL, Kurian, BT, Trivedi, MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010; 24(4):267–284.
American Psychiatric Association. Depressive Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2013:155–188.
Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry. 2016; 61(9):510–523.
Habert, J, Katzman, MA, Oluboka, OJ, et al. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord. 2016; 18(5).
Oluboka, OJ, Katzman, MA, Habert, J, et al. Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol. 2018; 21(2):128–144.
Machado, M, Iskedjian, M, Ruiz, I, Einarson, TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006; 22(9):1825–1837.
Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11):1905–1917.
Gormley, N, O’Leary, D, Costello, F. First admissions for depression: is the ‘no-treatment interval’ a critical predictor of time to remission? J Affect Disord. 1999; 54(1-2):49–54.
Okuda, A, Suzuki, T, Kishi, T, et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010; 64(3):268–273.
Bukh, JD, Bock, C, Vinberg, M, Kessing, LV. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord. 2013; 145(1):42–48.
Ghio, L, Gotelli, S, Marcenaro, M, Amore, M, Natta, W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord. 2014; 152-154:45–51.
Moylan, S, Maes, M, Wray, NR, Berk, M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013; 18(5):595–606.
Kennedy, SH, Lam, RW, McIntyre, RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9):540–560.
Soares, CN, Fayyad, RS, Guico-Pabia, CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014; 34(1):57–65.
DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007; 68(5):677–688.
Liebowitz, MR, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7):1877–1890.
Boyer, P, Montgomery, S, Lepola, U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23(5):243–253.
Tourian, KA, Padmanabhan, SK, Groark, J, Brisard, C, Farrington, D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009; 31 Pt 1:1405–1423.
Iwata, N, Tourian, KA, Hwang, E, Mele, L, Vialet, C, for the Study 3359 investigators. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013; 19(1):5–14.
Clayton, AH, Kornstein, SG, Dunlop, BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013; 74(10):1010–1017.
Dunlop, BW, Reddy, S, Yang, L, Lubaczewski, S, Focht, K, Guico-Pabia, CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011; 31(5):569–576.
Soares, CN, Endicott, J, Boucher, M, Fayyad, RS, Guico-Pabia, CJ. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr. 2014; 19(6):519–527.
Lam, RW, Endicott, J, Hsu, MA, Fayyad, R, Guico-Pabia, C, Boucher, M. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2014; 29(5):239–251.
Sheehan, DV. Sheehan Disability Scale. In: Rush, AJ, Pincus, HA, First, MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:113–115.
Liebowitz, MR, Tourian, KA, Hwang, E, Mele, L, for the Study 3362 investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry. 2013; 13(1):94.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56–62.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382–389.
Sheehan, DV, Harnett-Sheehan, K, Spann, ME, Thompson, HF, Prakash, A. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol. 2011; 26(2):75–83.
Sheehan, KH, Sheehan, DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008; 23(2):70–83.
Gallop, RJ. Determination and interpretation of the OOP for ROC’s with PROC LOGISTIC. Proceedings of the NorthEast SAS Users Group. Baltimore, MD: NorthEast SAS Users Group; 2001:777–782.
Gorwood, P, Vaiva, G, Corruble, E, Llorca, PM, Bayle, FJ, Courtet, P. The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatr Dis Treat. 2015; 11:2875–2882.
37.Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2018.
Thase, ME, Kornstein, SG, Germain, JM, Jiang, Q, Guico-Pabia, C, Ninan, PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectrums. 2009; 14(3):144–154.
Quitkin, FM, McGrath, PJ, Stewart, JW, Taylor, BP, Klein, DF. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology. 1996; 15(4):390–394.
Stewart, JW, Quitkin, FM, McGrath, PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998; 55(4):334–343.
Quitkin, FM, Taylor, BP, Kremer, C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001; 62(5):358–361.
Posternak, MA, Zimmerman, M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005; 66(2):148–158.
Stassen, HH, Angst, J, Hell, D, Scharfetter, C, Szegedi, A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry. 2007; 68(8):1195–1205.
Khan, A, Redding, N, Brown, WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008; 42(10):791–796.
Tokuoka, H, Takahashi, H, Ozeki, A, et al. Trajectories of depression symptom improvement and associated predictor analysis: an analysis of duloxetine in double-blind placebo-controlled trials. J Affect Disord. 2016; 196:171–180.
Henssler, J, Kurschus, M, Franklin, J, Bschor, T, Baethge, C. Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials. J Clin Psychiatry. 2018; 79(3).
Henssler, J, Kurschus, M, Franklin, J, Bschor, T, Baethge, C. Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2018; 79(1).
Kudlow, PA, McIntyre, RS, Lam, RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs. 2014; 28(7):601–609.